Since 1959 we have invested more than £55 million in high quality research into muscle-wasting conditions. This has been possible only through the generosity and dedication of our supporters.
We are investing in world-class, pioneering research into the development of treatments and eventually cures for people with muscle-wasting conditions.
Our new commitment of £1.45m will boost the world’s largest natural history study for Duchenne muscular dystrophy, known as NorthStar, and improve the quality of life for children and adults living with the condition.
The Oxford Neuromuscular Translational Research Centre will boost capacity for clinical trials. Working alongside the major centres in Newcastle and London, this third centre will be a game changer for individuals and families living with muscle-wasting conditions in the UK.
We are proud to be a long-standing supporter of research into gene therapy. This technology has advanced significantly over the years and it’s now time to take it to the next level: to test its safety in people living with muscle-wasting conditions in the UK.